FUL.L Regulatory News (FUL)

10 Mar 2008 07:00

Fulcrum Pharma PLC10 March 2008 10th March 2008 FULCRUM PHARMA PLC ("the Company") Appointment of new CEO Further to the announcement made on 10 January 2008, Fulcrum Pharma plc (AIM:FUL), the drug development and regulatory services company, announces that ithas today appointed Dr Frank Armstrong as its new Chief Executive Officer asfrom 1st April 2008. Dr. Armstrong has more than 20 years' experience at major pharmaceutical andleading biotechnology companies where he has been integral in bringing newpharmaceutical products to the market. Most recently, Dr. Armstrong was President and Chief Executive Office of CuraGenCorporation, a NASDAQ listed biopharmaceutical company, from March 2006 untilSeptember 2007. Prior to CuraGen, Dr. Armstrong was CEO of BioaccelerateHoldings Inc., Provensis Ltd. and Phoqus Pharmaceuticals plc. From 1998 to 2001,Dr. Armstrong was Executive Vice President and Head of Worldwide ProductDevelopment for Bayer AG, Germany, and from 1985 to 1998 served in various roleswith ICI Pharmaceuticals, then Zeneca in the UK and USA where his final positionwas Senior Vice President of the Medical Research and Communications Group. Dr. Armstrong received his MBChB from the University of Edinburgh and became amember of the Royal College of Physicians in 1984. He was elected a Fellow ofthe Royal College of Physicians, Edinburgh, in 1993 and elected a Fellow of theFaculty of Pharmaceutical Physicians in 1994. Sir Charles George, Chairman of Fulcrum Pharma, said: "The Board is delighted to welcome Dr Armstrong as Fulcrum's new CEO. Frankbrings a wealth of leadership experience from a wide range of companies withinour industry that will be invaluable in guiding Fulcrum in the next stages ofour growth. "I also wish to thank Dr Jon Court for having steered Fulcrum to where we aretoday as its CEO and welcome him to his new role as Director of StrategicBusiness Development." For further information, please contact: Fulcrum Pharma PLCGeoffrey Smith, Finance Director Tel: 01442 283600 Seymour PierceJonathan Wright Tel: 0207 107 9000 About Fulcrum Pharma plc Fulcrum Pharma plc is a drug development and regulatory services business thatprovides global expertise to achieve drug development and regulatory approvalmilestones. Fulcrum Pharma offers immediate access to a highly credible,integrated development team that provides strategic and operational leadershiprequired to ensure that new drugs move smoothly from discovery research toproduct approval Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange havingsuccessfully floated in March 2000. Notes: Dr. Frank Murdoch Armstrong, age 51, is currently a director of CuraGenCorporation. Within the past five years, he has been a director of the followingcompanies: 454 Life Sciences CorporationBioaccelerate Holdings, Inc.Provensis LimitedPhoqus Pharmaceuticals (UK) LimitedPhoqus Pharmaceuticals plcAvidex Limited (now named Medigene Limited) This information is provided by RNS The company news service from the London Stock Exchange